Nirmatrelvir-ritonavir no aid for long COVID symptoms
Jun 10, 2024
The findings based on symptoms at 10 weeks following 15-day course in vaccinated cohort.
More free COVID-19 tests made available by US government
Nov 20, 2023
Four tests are allowed per household; people who did not order more in September can order up to eight free tests.
Immune response not inferior with coadministration of COVID-19, flu shots
Sep 14, 2023
A similar immune response and no increase in the rate of reactogenicity events was seen with coadministration versus administering the COVID-19 vaccine alone.
Viral rebound uncommon after molnupiravir, nirmatrelvir-ritonavir therapy
Dec 09, 2022
Viral rebound was uncommon with treatment for patients hospitalized with COVID-19 and not associated with increased mortality.
Minimal change in mental health linked to COVID-19
Mar 09, 2023
In general population studies, no change was observed in general mental health or anxiety symptoms; minimal worsening was seen in depression symptoms.
Risk for first-time clot events raised after COVID-19 diagnosis
Sep 29, 2022
The incidence is highest in the first week but remains elevated up to 49 weeks after COVID-19 diagnosis.
Ending state of emergency won’t change staffing needs, provider group says
By
Kathleen Steele Gaivin
Sep 22, 2022
ency on Oct. 31, long-term care staffing needs have not abated, and lifting the order could affect regulations that have permitted additional flexibility in staffing. That’s according to the Washington...
Seniors had high burden of RSV-positive respiratory infection before COVID-19
Jan 23, 2023
Following a sharp decline during COVID-19, RSV-positive acute respiratory infection re-emerged during the summer of 2021 and is linked to lower quality of life.
Paxlovid soon will not be free for Americans
Dec 07, 2022
At this point, about 6 million Americans have taken free Paxlovid doses.
Natural protection against reinfection with BA.1 COVID-19 variant lower
Feb 17, 2023
However, protection against severe disease remains high, at 88.9%, for omicron BA.1 at 40 weeks.